In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies).

Marta Hernandez-GarcíaMaría García-CastilloJosé Melo-CristinoMargarida F PintoElsa GonçalvesValquíria AlvesAna Raquel VieiraElmano RamalheiraLuísa SanchoJosé DiogoRui FerreiraHugo CruzCatarina ChavesGermán BouEmilia CercenadoMercedes Delgado-ValverdeAntonio OliverCristina PitartJesús Rodríguez-LozanoNuria TormoJazmín Díaz-RegañónLeonor PássaroJoana DuarteRafael Cantónnull null

Published in: The Journal of antimicrobial chemotherapy (2022)

Microbiological results reinforce imipenem/relebactam as a potential option to treat cUTI, cIAI and LRTI caused by MDR/XDR P. aeruginosa isolates, except for GES-13 and VIM producers.

Keyphrases

pseudomonas aeruginosa
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
intensive care unit
drug resistant
multidrug resistant
cystic fibrosis
prognostic factors
peritoneal dialysis
climate change
human health
extracorporeal membrane oxygenation
patient reported